Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 126 of 1,261
  1. US 11944644

    T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  2. US 11944687

    Carbohydrate conjugate RNA agents and process for their preparation

    Alnylam Pharmaceuticals, Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  3. US 11946065

    Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB

    The Board of Regents of the University of Texas System Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  4. US 11944532

    Engineered tendon graft for rotator cuff repair

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  5. US 11944656

    Microbials for feed

    MICROBIAL DISCOVERY GROUP, LLC Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  6. US 11944658

    Methods of heat inactivation of adenovirus

    Ultragenyx Pharmaceutical Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  7. US 11944683

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  8. US 11946049

    tRNA/pre-miRNA compositions and use in treating cancer

    The Regents of the University of California Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  9. US 11945794

    Nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  10. US 11945855

    Recombinant polypeptides comprising modified MHC class II DRa1 domains and methods of use

    United States Government as represented by the Department of Veterans Affairs Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  11. US 11944627

    Methods for treating hematological malignancies and Ewing's sarcoma

    Kura Oncology, Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  12. US 11944617

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Corcept Therapeutics Incorporated Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  13. US 11944679

    Genome-wide identification of immune evasion functions in a virus

    The Regents of the University of California Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  14. US 11945824

    Heterocyclic compounds as anti-viral agents

    Enanta Pharmaceuticals, Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  15. US 11944614

    Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  16. US 11944666

    Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  17. US 11945778

    C4-carbonothioate-substituted tryptamine derivatives and methods of using

    Enveric Biosciences Canada Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  18. US 11945830

    Antiviral heterocyclic compounds

    Enanta Pharmaceuticals, Inc. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  19. US 11945872

    Anti-ACVR1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  20. US 11945795

    Islet cell manufacturing compositions and methods of use

    Vertex Pharmaceuticals Incorporated Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  21. US 11945822

    Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase

    Lead Discovery Center GmbH Β· Granted Apr 2, 2024 Β· Expires Mar 28, 2044

    granted
  22. WO 2024064327

    OLIGOSACCHARIDES DE LAIT HUMAIN POUR AMΓ‰LIORER LA FONCTION DE BARRIÈRE HΓ‰MATO-ENCΓ‰PHALIQUE

    ABBOTT LAB [US] Β· Granted Mar 28, 2024 Β· Expires Mar 23, 2044

    granted
  23. CA 3263063

    VELUSETRAG DESTINΓ‰ Γ€ ÊTRE UTILISΓ‰ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)

    ALFASIGMA SPA [IT] Β· Granted Mar 28, 2024 Β· Expires Mar 23, 2044

    granted
  24. US 11939361

    Compositions of peptide inhibitors of Interleukin-23 receptor

    Protagonist Therapeutics, Inc. Β· Granted Mar 26, 2024 Β· Expires Mar 21, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.